JPMorgan's Take on Roivant Sciences (ROIV) Buyback and Positive Data Annoucement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Truist Securities sees Roivant Sciences (ROIV) shares up today on positive brepocitinib data
April 2, 2024 8:04 AM EDTTruist Securities analyst Robyn Karnauskas reiterated a Buy rating and $23.00 price target on Roivant Sciences (NASDAQ: ROIV), saying positive brepocitinib data supports potential success in NIU.
The analyst commented, "We believe Roivant shares could be up today following announcement of positive Ph2 results for... More
Roivant Sciences (ROIV) Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, $1.5B Share Buyback
April 2, 2024 7:02 AM EDTRoivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 2 study (NEPTUNE) evaluating brepocitinib in non-anterior non-infectious uveitis (NIU), showing the strongest efficacy data in NIU observed to date. Roivant also announced that its board of directors has authorized a share repurchase program for up to $1.5 billion of the companys common shares, including the repurchase of all 71.3 million shares held by Sumitomo Pharma at a purchase price of $9.10 per share. The aggregate purchase price for the Sumitomo Pharma transaction is approximately $648.4 million and will reduce Roivants shares outstanding as of February 9, 2024... More
